These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 38252223)

  • 21. The impact of filgotinib on patient-reported outcomes and health-related quality of life for patients with active rheumatoid arthritis: a post hoc analysis of Phase 3 studies.
    Bingham CO; Walker D; Nash P; Lee SJ; Ye L; Hu H; Khalid JM; Combe B
    Arthritis Res Ther; 2022 Jan; 24(1):11. PubMed ID: 34980223
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Upadacitinib improves patient-reported outcomes vs placebo or adalimumab in patients with rheumatoid arthritis: results from SELECT-COMPARE.
    Strand V; Tundia N; Bergman M; Ostor A; Durez P; Song IH; Enejosa J; Schlacher C; Song Y; Fleischmann R
    Rheumatology (Oxford); 2021 Dec; 60(12):5583-5594. PubMed ID: 33590829
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugs.
    Strand V; Schiff M; Tundia N; Friedman A; Meerwein S; Pangan A; Ganguli A; Fuldeore M; Song Y; Pope J
    Arthritis Res Ther; 2019 Dec; 21(1):263. PubMed ID: 31791386
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) scale in patients with axial spondyloarthritis: psychometric properties and clinically meaningful thresholds for interpretation.
    Cella D; de la Loge C; Fofana F; Guo S; Ellis A; Fleurinck C; Massow U; Dougados M; Navarro-Compán V; Walsh JA
    J Patient Rep Outcomes; 2024 Aug; 8(1):92. PubMed ID: 39133438
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Improved health outcomes with etanercept versus usual DMARD therapy in an Asian population with established rheumatoid arthritis.
    Bae SC; Gun SC; Mok CC; Khandker R; Nab HW; Koenig AS; Vlahos B; Pedersen R; Singh A
    BMC Musculoskelet Disord; 2013 Jan; 14():13. PubMed ID: 23294908
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Secukinumab treatment in rheumatoid arthritis is associated with incremental benefit in the clinical outcomes and HRQoL improvements that exceed minimally important thresholds.
    Strand V; Kosinski M; Gnanasakthy A; Mallya U; Mpofu S
    Health Qual Life Outcomes; 2014 Mar; 12():31. PubMed ID: 24597620
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tofacitinib in Combination With Conventional Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis: Patient-Reported Outcomes From a Phase III Randomized Controlled Trial.
    Strand V; Kremer JM; Gruben D; Krishnaswami S; Zwillich SH; Wallenstein GV
    Arthritis Care Res (Hoboken); 2017 Apr; 69(4):592-598. PubMed ID: 27565000
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comprehensive disease control (CDC): what does achieving CDC mean for patients with rheumatoid arthritis?
    Emery P; Kavanaugh A; Bao Y; Ganguli A; Mulani P
    Ann Rheum Dis; 2015 Dec; 74(12):2165-74. PubMed ID: 25139667
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of tocilizumab monotherapy on patient-reported outcomes in patients with rheumatoid arthritis from two randomised controlled trials.
    Strand V; Michalska M; Birchwood C; Pei J; Tuckwell K; Finch R; Gabay C; Kavanaugh A; Jones G
    RMD Open; 2017; 3(2):e000496. PubMed ID: 28955499
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical meaningfulness of a British Isles Lupus Assessment Group-based Composite Lupus Assessment response in terms of patient-reported outcomes in moderate to severe systemic lupus erythematosus: a post-hoc analysis of the phase 3 TULIP-1 and TULIP-2 trials of anifrolumab.
    Strand V; O'Quinn S; Furie RA; Morand EF; Kalunian KC; Schwetje EG; Abreu G; Tummala R
    Lancet Rheumatol; 2022 Mar; 4(3):e198-e207. PubMed ID: 38288936
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Psychometric evaluation of the NTDT-PRO questionnaire for assessing symptoms in patients with non-transfusion-dependent beta-thalassaemia.
    Taher AT; Musallam KM; Viprakasit V; Kattamis A; Lord-Bessen J; Yucel A; Guo S; Pelligra C; Shields AL; Shetty JK; Miteva D; Bueno LM; Cappellini MD
    BMJ Open; 2023 Mar; 13(3):e066683. PubMed ID: 36948565
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinically important changes in short form 36 health survey scales for use in rheumatoid arthritis clinical trials: the impact of low responsiveness.
    Ward MM; Guthrie LC; Alba MI
    Arthritis Care Res (Hoboken); 2014 Dec; 66(12):1783-9. PubMed ID: 24980417
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Delayed-release prednisone improves fatigue and health-related quality of life: findings from the CAPRA-2 double-blind randomised study in rheumatoid arthritis.
    Alten R; Grahn A; Holt RJ; Rice P; Buttgereit F
    RMD Open; 2015; 1(1):e000134. PubMed ID: 26535146
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Patient-reported Health-related Quality of Life with apremilast for psoriatic arthritis: a phase II, randomized, controlled study.
    Strand V; Schett G; Hu C; Stevens RM
    J Rheumatol; 2013 Jul; 40(7):1158-65. PubMed ID: 23588944
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sarilumab improves patient-reported outcomes in rheumatoid arthritis patients with inadequate response/intolerance to tumour necrosis factor inhibitors.
    Strand V; Reaney M; Chen CI; Proudfoot CW; Guillonneau S; Bauer D; Mangan E; Graham NM; van Hoogstraten H; Lin Y; Pacheco-Tena C; Fleischmann R
    RMD Open; 2017; 3(1):e000416. PubMed ID: 28326189
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Functional Assessment of Chronic Illness Therapy-Fatigue is a reliable and valid measure in patients with active ankylosing spondylitis.
    Cella D; Lenderking WR; Chongpinitchai P; Bushmakin AG; Dina O; Wang L; Cappelleri JC; Navarro-Compán V
    J Patient Rep Outcomes; 2022 Sep; 6(1):100. PubMed ID: 36138330
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect of intravenous golimumab on health-related quality of life in rheumatoid arthritis: 24-week results of the phase III GO-FURTHER trial.
    Bingham CO; Weinblatt M; Han C; Gathany TA; Kim L; Lo KH; Baker D; Mendelsohn A; Westhovens R
    J Rheumatol; 2014 Jun; 41(6):1067-76. PubMed ID: 24786931
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Group cognitive-behavioural programme to reduce the impact of rheumatoid arthritis fatigue: the RAFT RCT with economic and qualitative evaluations.
    Hewlett S; Almeida C; Ambler N; Blair PS; Choy E; Dures E; Hammond A; Hollingworth W; Kadir B; Kirwan J; Plummer Z; Rooke C; Thorn J; Turner N; Pollock J
    Health Technol Assess; 2019 Oct; 23(57):1-130. PubMed ID: 31601357
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical significance of lifetime mood and panic-agoraphobic spectrum symptoms on quality of life of patients with rheumatoid arthritis.
    Piccinni A; Maser JD; Bazzichi L; Rucci P; Vivarelli L; Del Debbio A; Catena M; Bombardieri S; Dell'Osso L
    Compr Psychiatry; 2006; 47(3):201-8. PubMed ID: 16635649
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Improved health-related quality of life for patients with active rheumatoid arthritis receiving rituximab: Results of the Dose-Ranging Assessment: International Clinical Evaluation of Rituximab in Rheumatoid Arthritis (DANCER) Trial.
    Mease PJ; Revicki DA; Szechinski J; Greenwald M; Kivitz A; Barile-Fabris L; Kalsi J; Eames J; Leirisalo-Repo M
    J Rheumatol; 2008 Jan; 35(1):20-30. PubMed ID: 18050385
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.